- Home
- AARD vs AUDC Comparison
AARD vs AUDC Comparison
Compare AARD & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- AUDC
- Stock Information
- Founded
- AARD 2017
- AUDC 1992
- Country
- AARD United States
- AUDC Israel
- Employees
- AARD N/A
- AUDC N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- AUDC Telecommunications Equipment
- Sector
- AARD Health Care
- AUDC Utilities
- Exchange
- AARD Nasdaq
- AUDC Nasdaq
- Market Cap
- AARD 242.9M
- AUDC 282.4M
- IPO Year
- AARD 2025
- AUDC 1999
- Fundamental
- Price
- AARD $8.59
- AUDC $9.25
- Analyst Decision
- AARD Strong Buy
- AUDC Buy
- Analyst Count
- AARD 5
- AUDC 3
- Target Price
- AARD $32.60
- AUDC $11.67
- AVG Volume (30 Days)
- AARD 77.3K
- AUDC 102.2K
- Earning Date
- AARD 08-13-2025
- AUDC 07-29-2025
- Dividend Yield
- AARD N/A
- AUDC 4.32%
- EPS Growth
- AARD N/A
- AUDC 3.22
- EPS
- AARD N/A
- AUDC 0.46
- Revenue
- AARD N/A
- AUDC $243,249,000.00
- Revenue This Year
- AARD N/A
- AUDC $2.52
- Revenue Next Year
- AARD N/A
- AUDC $1.74
- P/E Ratio
- AARD N/A
- AUDC $20.84
- Revenue Growth
- AARD N/A
- AUDC N/A
- 52 Week Low
- AARD $4.88
- AUDC $7.70
- 52 Week High
- AARD $19.58
- AUDC $12.72
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- AUDC 43.36
- Support Level
- AARD N/A
- AUDC $9.12
- Resistance Level
- AARD N/A
- AUDC $9.80
- Average True Range (ATR)
- AARD 0.00
- AUDC 0.24
- MACD
- AARD 0.00
- AUDC -0.01
- Stochastic Oscillator
- AARD 0.00
- AUDC 28.81
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.